The structural network of Interleukin-10 and its implications in inflammation and cancer

Abstract

BackgroundInflammation has significant roles in all phases of tumor development, including initiation, progression and metastasis. Interleukin-10 (IL-10) is a well-known immuno-modulatory cytokine with an anti-inflammatory activity. Lack of IL-10 allows induction of pro-inflammatory cytokines and hinders anti-tumor immunity, thereby favoring tumor growth. The IL-10 network is among the most important paths linking cancer and inflammation. The simple node-and-edge network representation is useful, but limited, hampering the understanding of the mechanistic details of signaling pathways. Structural networks complete the missing parts, and provide details. The IL-10 structural network may shed light on the mechanisms through which disease-related mutations work and the pathogenesis of malignancies.ResultsUsing PRISM (a PRotein Interactions by Structural Matching tool), we constructed the structural network of IL-10, which includes its first and second degree protein neighbor interactions. We predicted the structures of complexes involved in these interactions, thereby enriching the available structural data. In order to reveal the significance of the interactions, we exploited mutations identified in cancer patients, mapping them onto key proteins of this network. We analyzed the effect of these mutations on the interactions, and demonstrated a relation between these and inflammation and cancer. Our results suggest that mutations that disrupt the interactions of IL-10 with its receptors (IL-10RA and IL-10RB) and α2-macroglobulin (A2M) may enhance inflammation and modulate anti-tumor immunity. Likewise, mutations that weaken the A2M-APP (amyloid precursor protein) association may increase the proliferative effect of APP through preventing β-amyloid degradation by the A2M receptor, and mutations that abolish the A2M-Kallikrein-13 (KLK13) interaction may lead to cell proliferation and metastasis through the destructive effect of KLK13 on the extracellular matrix.ConclusionsPrediction of protein-protein interactions through structural matching can enrich the available cellular pathways. In addition, the structural data of protein complexes suggest how oncogenic mutations influence the interactions and explain their potential impact on IL-10 signaling in cancer and inflammation.

Inhibitors of kallikrein‐related peptidases: An overview

“…α2M inhibits KLK1, KLK2, KLK3, and KLK13 . This globulin is also capable of trapping any protease having a lysine residue at its surface.…”

A Structural View of Negative Regulation of the Toll-like Receptor-Mediated Inflammatory Pathway

“…Subsequently, MyD88-dependent TIR domain signalosome recruits IRAK4, IRAK2/IRAK1, and TRAF6, which lead to activation of the nuclear factor-kappa B (NF-kB) and mitogen-activated protein kinases (MAPKs), and transcription of proinflammatory cytokines, like interleukin (IL)-1b and tumor necrosis factor (TNF)-a (1). The TRIF-dependent TIR domain signalosome employs TRAF3 to activate interferon-regulatory factors (IRFs) to induce transcription of antiviral interferons (IFNs) and antiinflammatory IL-10 (11,12).…”

Blood‐based protein predictors of dementia severity as measured by δ: Replication across biofluids and cohorts

“…IL‐10 is a key ANTI‐inflammatory cytokine, associated with multiple other pro‐ and anti‐inflammatory proteins in a complex network [42]. IL‐12 is a similarly important PRO‐inflammatory protein, and antagonizes many of IL‐10's effects.…”